BHVN
Biohaven Ltd.
$16.05
+0.09 (+0.56%)
At close · Jul 6
Market Cap
$2.42B
Shares
150,560,990
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.05
Open$16.10
Day$15.72–16.44
52W$7.48–18.57
Avg vol 30d3.5M
Short int25.5M · 16.9% float · 8.1d
Short vol43%
Last earningsMay 27, 2026
DataSep 2022–Jul 2026
Filing10-Q · May 4
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+38% above
+
Price vs 50-day avg
+42% above
−
RSI (14)
71 · overbought
+
MACD trend
positive
◦
52-week position
77% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $11 › 200d $12 — 200d above 50d
+
Institutional flow
3 of 276 funds reported for Jun 30 · net +267 sh shares
◦
Insider flow
No net insider activity over 90 days
−
Short interest
16.94% of float · ▲ +1.0% MoM · 8.1 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
276 holders — near 3-yr high, broad support
Fundamentals
Strong
+
EPS growth
+26% Y/Y
−
Free cash flow
$-610.2M
+
Balance sheet
net cash $230.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 26, 2026
Est · unconfirmed
· in 7 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+38% above
Bullish
Price vs 50-day avg
+42% above
Bullish
RSI (14)
71 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
77% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $11 › 200d $12 — 200d above 50d
Institutional flow
Accumulating
3 of 276 funds reported for Jun 30 · net +267 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.94% of float · ▲ +1.0% MoM · 8.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
276 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $7
Now $16 · 77%
52-wk high $19
vs 200-day avg +38%
vs 50-day avg +42%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BHVN
this stock
Biohaven Ltd.
|
$2.42B | +42.2% | — | — | 16.9% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BHVN | +1.4% | +40.8% | +44.5% | +7.9% | +42.2% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -1.7% | +41.6% | +36.2% | +7.3% | +32.0% |